| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02723955 |
| P698 | PubMed publication ID | 11262989 |
| P2093 | author name string | Mauldin J | |
| P2860 | cites work | A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A | Q77790082 |
| Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects | Q22337418 | ||
| First trimester screening for aneuploidy: serum biochemical markers | Q33768998 | ||
| First trimester screening for aneuploidy: nuchal translucency sonography | Q33769004 | ||
| First trimester prenatal diagnosis: fetal cells in the maternal circulation | Q33769015 | ||
| Open fetal surgery for life-threatening fetal malformations | Q33814208 | ||
| Fetal surgery for myelomeningocele | Q33814214 | ||
| First-trimester screening for aneuploidy: research or standard of care? | Q33876710 | ||
| Endoscopic coverage of fetal myelomeningocele in utero | Q34488855 | ||
| Increased nuchal translucency as a marker for fetal chromosomal defects | Q34743694 | ||
| PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies | Q35249607 | ||
| Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus | Q38498652 | ||
| Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. | Q38507170 | ||
| Isolating fetal cells from maternal blood. Advances in prenatal diagnosis through molecular technology | Q40775838 | ||
| Antenatal screening for Down's syndrome. | Q40909255 | ||
| Risks associated with an elevated maternal serum a-fetoprotein level | Q44459522 | ||
| Fetal sonographic findings: analysis of the most frequent patterns and their specificity of association | Q44507746 | ||
| First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. | Q45291831 | ||
| Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha‐fetoprotein, unconjugated oestriol, and human chorionic gonadotropin | Q46274386 | ||
| Maternal serum screening for alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities | Q46300167 | ||
| Second-Trimester Maternal Serum Alpha-Fetoprotein Levels and the Risk of Subsequent Fetal Death | Q46623914 | ||
| First trimester fetal nuchal translucency: problems with screening the general population. 2. | Q47337182 | ||
| 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome | Q47895475 | ||
| Maternal serum alpha-fetoprotein and dimeric inhibin A detect aneuploidies other than Down syndrome. | Q50860489 | ||
| Scientific and ethical issues of preimplantation diagnosis. | Q50894422 | ||
| Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. | Q52255440 | ||
| Maternal serum screening for Down syndrome in the United States: a 1995 survey. | Q53970056 | ||
| Successful fetal surgery for spina bifida | Q56168701 | ||
| UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation | Q57523616 | ||
| The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications | Q68150725 | ||
| Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice | Q71753811 | ||
| Fetal cells in maternal circulation throughout gestation | Q72674874 | ||
| Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome | Q73083850 | ||
| Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters | Q73543354 | ||
| First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency | Q74223487 | ||
| Results of routine fetal nuchal translucency measurement at weeks 10-13 in 4233 unselected pregnant women | Q74246537 | ||
| Evaluation of first-trimester screening by fetal nuchal translucency and maternal age | Q74356914 | ||
| Screening of maternal serum for fetal Down's syndrome in the first trimester | Q74378735 | ||
| Antenatal screening for Down's syndrome: where are we and where next? | Q77151494 | ||
| First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness | Q77327757 | ||
| Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population | Q77479776 | ||
| First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test | Q77748767 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 899-905 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Indian Journal of Pediatrics | Q26842079 |
| P1476 | title | Prenatal diagnosis and fetal therapy--what lies in future? | |
| P478 | volume | 67 |
| Q90275396 | Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques | cites work | P2860 |
Search more.